Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F. Kelley, Renu Singh, Maribel Acevedo-Quiñones et al.|New England Journal of Medicine|2024Cited by 260
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Jason Flamm, Peter Ruane et al.|The Lancet HIV|2021Cited by 91
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Martin S. Rhee, Frank A. Post et al.|The Lancet HIV|2018Cited by 27
Predictors of Early Neurodevelopmental Outcomes for Children with Congenital Heart Disease: A Report from the Cardiac Neurodevelopmental Outcome CollaborativeMike Seed, Thomas L. Miller, Jennifer Butcher et al.|medRxiv|2025Cited by 1